| Outcome Measures: |
Primary: HbA1c, The change in mean HbA1c concentrations (%)from baseline with Efsubaglutide Alfa 3mg QoW versus Efsubaglutide Alfa 1mg QW, 12 weeks | Secondary: TIR, Changes in the percentage of time in range (TIR) relative to baseline, 12 weeks|HbA1c<7.0% and <6.5%, The proportion of participants who achieved HbA1c target (HbA1c\<7.0% and \<6.5% Patient percentage), 12 weeks|fasting lipid profiles, Changes in fasting lipid(TC/TG/HDL-C/LDL-C) profiles relative to baseline(mmol/L), 12 weeks|weight, Weight change from baseline(kg), 12 weeks|waist circumference, Absolute changes in waist circumference(cm) from baseline, 12 weeks|hip circumference, Absolute changes in hip circumference(cm) from baseline, 12 weeks|waist-to-hip ratio (WHR), Absolute changes in waist-to-hip ratio (WHR) from baseline, 12 weeks|salvage treatment, Percentage of subjects receiving salvage treatment(%), 12 weeks|body fat composition, Changes in body fat composition from baseline, 12 weeks|FPG, Changes in FPG (mmol/L) relative to baseline, 12 weeks
|
